Sunday, November 15, 2026

Peer-Reviewed Clinical Evidence Platform

The research that matters, without the jargon.

Peer-reviewed breakthroughs in plain English alongside verified outcomes, evidence grades, and clinical study details for everyone from everyday readers to medical students.

ClearMed Editorial Digest500 briefings across 12 specialties121 Phase III & clinical practice

Indexed from PubMed, NEJM, The Lancet, JAMA, Nature MedicineSaved Library

Health Hubs:

Stage: Evidence:

Showing 6 briefings matching “inflammation”

Reset all filters

Gastroenterology

Gastroenterology Clinical Briefings

Peer-Reviewed Clinical Digests · Verified Scientific Media

Gastroenterology editorial photograph for TASTY AND HEALTHY DIET REDUCES FECAL CALPROTECTIN IN HIGH-RISK FIRST-DEGREE RELATIVES OF PATIENTS WITH CROHN'S DISEASE: PIONIR RANDOMIZED CROSSOVER TRIAL

GASTROENTEROLOGY · RANDOMIZED CLINICAL TRIAL

TASTY AND HEALTHY DIET REDUCES FECAL CALPROTECTIN IN HIGH-RISK FIRST-DEGREE RELATIVES OF PATIENTS WITH CROHN'S DISEASE: PIONIR RANDOMIZED CROSSOVER TRIAL

With the rising prevalence of inflammatory bowel disease (IBD), preventing new-onset disease becomes a priority. The PIONIR (Preventing IBD ONset in Individuals at Risk) randomized controlled trial explored whether the Tasty&Healthy (T&H) diet reduces inflammatory markers in high-risk first-degree relatives (FDRs) of patients with Crohn's disease (CD).

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readGastroenterologyOct 26, 2026

GASTROENTEROLOGY · PHASE III

Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 48-week results from a multicentre, randomised, double-blind, phase 2b study

In patients with MASH, 48 weeks of pemvidutide treatment led to significant reductions in non-invasive tests of MASH inflammation and fibrosis (tissue scarring), suggesting continued improvement in liver health. These data warrant the continued investigation of pemvidutide in a Phase 3 trial.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readThe Lancet Gastroenterology & HepatologyNov 11, 2026

GASTROENTEROLOGY · PRECLINICAL

Single-cell landscape of alcohol-related hepatitis reveals serum amyloid a hepatocytes as key drivers of disease pathogenesis

The SAA-FPR2 pathway emerges as a potential mediator of inflammation in AH, offering potential therapeutic targets for this severe disease. This study provides new insights into the cellular heterogeneity and dynamics in ALD progression, dissecting AH at a single-cell level.

2/5 Preclinical

Evidence Meter · 2/5

Animal & Preclinical Data

Demonstrated in living animal models before large-scale human safety and dosing trials begin.

1 min readHepatology (baltimore, Md.)Oct 23, 2026

GASTROENTEROLOGY · RANDOMIZED CLINICAL TRIAL

Microbiota-Taurine Pathway Links Dietary Fiber to Mucosal Healing

Alginate engages a fiber-microbiota-taurine-epithelial signaling pathway that promotes recovery in preclinical models. The clinical trial did not meet its primary endpoint; however, the biological changes warrant further investigation of alginate as a microbiota-targeted intervention.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readGastroenterologyOct 21, 2026

GASTROENTEROLOGY · META-ANALYSIS

Updated treatment targets in inflammatory bowel disease (STRIDE-III): an initiative of the International Organization for the Study of IBD

This framework supports consistent, evidence-based treat-to-target care. Adjunctive targets (ie, urgency, histological remission in ulcerative colitis, transmural remission in Crohn's disease, and growth) are supported by studies showing association with favourable outcomes and guide treatment optimisation and tighter monitoring but do not necessarily require a change in therapeutic class.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readThe Lancet Gastroenterology & HepatologyOct 19, 2026

GASTROENTEROLOGY · REAL-WORLD COHORT

Myofibroblast-Derived Transglutaminase 2 Activity is Upregulated in Stricturing Crohn's Disease and Its Inhibition Exerts Antifibrotic Properties

TG2 may be involved in inflammation-independent progression of intestinal fibrosis (tissue scarring). Excessive accumulation of extracellular matrix (ECM) derived from human intestinal myofibroblasts (HIMFs) drives the significant clinical problem of intestinal fibrosis.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readGastroenterologyOct 13, 2026

Interactive Fact Check